A new class of drug for the management of type 2 diabetes: Sodium glucose co-transporter inhibitors: 'Glucuretics'

Diabetes and Metabolic Syndrome: Clinical Research and Reviews

Volumn 6, Issue 4, 2012, Pages 224-228

  Esther Chan, H W ^a   Ashan, B ^b   Jayasekera, P ^b   Collier, Andrew ^a   Ghosh, Sujoy ^c  

^a AYR HOSPITAL   (United Kingdom)

^b ROYAL BERKSHIRE HOSPITAL   (United Kingdom)

^c INSTITUTE OF POST GRADUATE MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

HbA1c; Infection; Phlorozin; Sodium glucose co transporter inhibitors; Type 2 diabetes

Indexed keywords

C PEPTIDE; DAPAGLIFLOZIN; ELECTROLYTE; GLUCOSE; GLUCOSE TRANSPORTER; INSULIN; METFORMIN; NEW DRUG; PHLORIZIN; REMOGLIFLOZIN ETABONATE; SERGLIFLOZIN ETABONATE; SODIUM GLUCOSE COTRANSPORTER 2;

DOSE RESPONSE; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG SCREENING; DRUG STABILITY; DRUG TOLERABILITY; DRUG URINE LEVEL; ELECTROLYTE URINE LEVEL; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLUCOSE TRANSPORT; GLUCOSURIA; GLYCEMIC CONTROL; HEMATOCRIT; HUMAN; INSULIN BLOOD LEVEL; KIDNEY; KIDNEY TUBULE ABSORPTION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REVIEW; SYSTEMATIC REVIEW; TREATMENT DURATION;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; FEMALE; GLUCOSE TRANSPORTER TYPE 1; GLUCOSIDES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; MALE; PHLORHIZIN; SODIUM-GLUCOSE TRANSPORTER 2;

EID: 84870399547     PISSN: 18714021     EISSN: 18780334     Source Type: Journal    
DOI: 10.1016/j.dsx.2012.08.003     Document Type: Review

References (50)

1. S. Wild, G. Roglic, A. Green, R. Sicree, and H. King Global prevalence of diabetes. Estimates for the year 2000 and projections for 2030 Diabetes Care 27 2004 1047 1053 (Pubitemid 38579764)
2. American Diabetes Association Economic costs of diabetes in the U.S. in 2007 Diabetes Care 31 2008 596 615
3. UK Prospective Diabetes Study (UKPDS) Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications with type 2 diabetes (UKPDS 33) Lancet 352 1998 837 853
4. D.M. Nathan Finding new treatments for diabetes-how many, how fast, how good? New England Journal of Medicine 356 2007 437 440 (Pubitemid 46193068)
5. V.A. Fonseca, and K.D. Kulkarni Management of type 2 diabets: oral agents, insulin, and injectables Journal of the American Dietetic Association 108 2008 S29 S33
6. F.X. Pi-Sunyer The impact of weight gain on motivation, compliance, and metabolic control in patients with type diabetes Postgraduate Medical Journal 121 2009 94 107
7. S.E. Kahn, R.L. Hull, and K.M. Utzshneider Mechanisms linking obesity to insulin resistance in type 2 diabetes Nature 444 2006 840 846 (Pubitemid 46024990)
8. I. Idris, and R. Donnelly Sodium-glucose co-transporter inhibitors: an emerging new class of oral anti-diabetic drug Diabetes, Obesity and Metabolism 11 2009 79 88
9. G.L. Bakris, V.A. Fonseca, K. Sharma, and E.M. Wright Renal sodium-glucose transport: role in diabetes mellitus and potential clinical implications Kidney International 75 2009 1272 1277
10. A. Vella, and R.A. Rizza Metabolic disturbances in diabetes R.I.G. Holt, C.S. Cockram, FlyvbergA B.J. Goldstein, Textbook of diabetes 4th edition 2010 Wiley-Blackwell United Kingdom
11. J.E. Gerich Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications Diabetic Medicine 27 2010 136 142
12. H. Bergman, and D.R. Drury The relationship of kidney function to the glucose utilization of the extra-abdominal tissues American Journal of Physiology 124 1938 279 284
13. E. Ferrannini Sodium-glucose transporter-2 inhibition as an antidiabetic therapy Nephrology, Dialysis, Transplantation 25 2010 2041 2043
14. I.S. Wood, and P. Trayhurn Glucose transporters (GLUT and SGLT): expanded families of sugar transport proteins British Journal of Nutrition 89 2003 3 9 (Pubitemid 36187532)
15. +/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for d-glucose Journal of Clinical Investigation 93 1994 397 404
16. +/glucose cotransporter SGLT2 reveal a common mechanism for SGLT1 and SGLT2 Journal of Biological Chemistry 20 1996 32678 32683 (Pubitemid 27008690)
17. +-glucose cotransporters American Journal of Physiology 280 2001 F10 F18
18. +/glucose cotransporter 1 (SGLT1) Journal of Cellular Biochemistry 90 2003 339 346 (Pubitemid 37222202)
19. J.R. White Apple trees to sodium glucose co-transporter inhibitors: a review of SGLT2 inhibition Clinical Diabetes 28 2010 5 10
20. W.S. Lee, R.G. Wells, and M.A. Hediger The high affinity Na/glucose cotransporter. Re-evaluation and distribution of expression Journal of Biological Chemistry 1994 12032 12039
21. L. Rossetti, D. Smith, G.I. Shulman, D. Papachristou, and R.A. DeFronzo Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats Journal of Clinical Investigation 79 1987 1510 1515 (Pubitemid 17099657)
22. L. Rossetti, A. Giaccari, and R.A. DeFonzo Glucose toxicity Diabetes Care 13 1990 610 630 (Pubitemid 20169143)
23. E. Ferrannini The stunned β-cell: a brief history Cell Metabolism 11 2010 349 352
24. O. Blondel, D. Bailbe, and B. Portha Insulin resistance in rats with non-insulin-dependent diabetes induced by neonatal (5 days) streptozotocin: evidence for reversal following phlorizin treatment Metabolism: Clinical and Experimental 39 1990 787 793 (Pubitemid 20250989)
25. P.C. De Jonge, T. Wieringa, J.P. Van Putten, H.M. Krans, and K. Van Dam Phloretin - an uncoupler and an inhibitor of mitochondrial oxidative phosphorylation Biochimica et Biophysica Acta 722 1983 219 225 (Pubitemid 13165729)
26. W.H. Oldendorf, P.D. Crane, P.M. Lawner, and L.D. Braun Rapid, transient drop in brain glucose after intravenous phloretin or 3-0-methyl-d-glucose Stroke 14 1983 388 393 (Pubitemid 13100319)
27. A.H. Scheepers, G. Joost, and A. Schurmann The glucose transporter families SGLT and GLUT: molecular basis of normal and aberrant function Journal of Parenteral and Enteral Nutrition 28 2004 364 371 (Pubitemid 39121460)
28. W.G. Leen, J. Klepper, M.M. Verbeek, M. Lerfink, T. Hofste, and B.G. van Engelen Glucose transporter-1 deficiency syndrome: the expanding clinical and genetic spectrum of a treatable disorder Brain 133 2010 655 670
29. K. Tsujihara, M. Hongu, K. Saito, M. Inamasu, K. Arakawa, and A. Oku Na(+)-glucose cotransporter inhibitors as antidiabetics. I. Synthesis and pharmacological properties of 4′-dehydroxyphlorizin derivatives based on a new concept Chemical and Pharmaceutical Bulletin 44 1996 1174 1180 (Pubitemid 26247171)
30. M. Hongu, N. Funami, Y. Takahashi, K. Saito, K. Arakawa, and M. Matsumoto Na(+)-glucose cotransporter inhibitors as antidiabetic agents. III. Synthesis and pharmacological properties of 4′-dehydroxyphlorizin derivatives modified at the OH groups of the glucose moiety Chemical and Pharmaceutical Bulletin 46 1998 1545 1555 (Pubitemid 28531013)
31. A. Oku, K. Ueta, M. Nawano, K. Arakawa, T. Kano-Ishihara, and M. Matsumoto Antidiabetic effect of T-1095, an inhibitor of Na(+)-glucose cotransporter, in neonatally streptozotocin-treated rats European Journal of Pharmacology 391 2000 183 192 (Pubitemid 30138095)
32. K. Arakawa, T. Ishihara, A. Oku, M. Nawano, K. Ueta, and K. Kitamura Improved diabetic syndrome in C57BL/KsJ-db/db mice by oral administration of the Na(+)-glucose cotransporter inhibitor T-1095 British Journal of Pharmacology 132 2001 578 586 (Pubitemid 32142370)
33. +-glucose cotransporter inhibitor T-1095 causes sustained improvement in hyperglycemia and prevents diabetic neuropathy in Goto-Kakizaki rats Life Sciences 79 2005 2655 2668 (Pubitemid 40404055)
34. K. Katsuno, Y. Fujimori, Y. Takemura, M. Hiratochi, F. Itoh, and Y. Komatsu Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level Journal of Pharmacology and Experimental Therapeutics 320 2007 323 330 [Treatment of type 2 diabetes. J Med Chem 2008; 51: 1145-9] (Pubitemid 46025747)
35. K. Katsuno, Y. Fujimori, Y. Ishikawa-Takemuray, and M. Isaji Longterm treatment with sergliflozin etabonate improves disturbed glucose metabolism in KK-A(y) mice European Journal of Pharmacology 15 2009 98 104
36. Y. Fujimori, K. Katsuno, I. Nakashima, Y. Ishikawa-Takemura, H. Fujikura, and M. Isaji Remogliflozin etabonate, in a novel category of selective low-affinity sodium glucose cotransporter (SGLT2) inhibitors, exhibits antidiabetic efficacy in rodent models Journal of Pharmacology and Experimental Therapeutics 237 2008 268 276
37. S. Han, D.L. Hagan, J.R. Taylor, L. Xin, W. Meng, and S.A. Biller Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats Diabetes 57 2008 1723 1729
38. F.R. Macdonald, J.E. Peel, H.B. Jones, R.M. Mayers, L. Westgate, and J.M. Whaley The novel sodium glucose transporter 2 inhibitor dapagliflozin sustains pancreatic function and preserves islet morphology in obese, diabetic rats Diabetes, Obesity and Metabolism 12 2010 1004 1012
39. B. Komoroski, N. Vachharajani, D. Boulton, D. Kornhauser, M. Geraldes, and L. Li Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects Clinical Pharmacology and Therapeutics 85 2009 520 526
40. M. Obermeister, M. Yao, A. Khanna, B. Kaplowitz, M. Zhu, and W. Li In vitro characterisation and pharmokinetics of dapagliflozin (BMS-512148), a potent sodium glucose cotransporter type 11 inhibitor, in animals and humans Drug Metabolism and Disposition: The Biological Fate of Chemicals 38 2010 405 414
41. R. Santer, M. Kinner, C.L. Lassen, R. Schneppenheim, P. Eggert, M. Bald, J. Brodehl, M. Daschner, J.H. Ehrich, M. Kemper, S. Li Volti, T. Neuhaus, F. Skovby, P.G. Swift, J. Schaub, and D. Klaerke Molecular analysis of the SGLT2 gene in patients with renal glucosuria Journal of the American Society of Nephrology 14 2003 2873 2882 (Pubitemid 37305650)
42. J. Calado, Y. Sznajer, D. Metzger, A. Rita, M.C. Hogon, and A. Kathamiss Twenty-one additional cases of familial renal glucosuria: absence of genetic heterogeneity, high prevalence of private mutations and futher evidence of volume depletion Nephrology, Dialysis, Transplantation 23 2008 3874 3879
43. E.K. Hussey, R.V. Clark, D.M. Amin, M.S. Kipnes, R.L. O'Connor-Semmes, and E.C. O'Driscoll Single-dose pharmacokinetics and pharmacodynamics of sergliflozin etabonate, a novel inhibitor of glucose reabsorption, in healthy volunteers and patients with type 2 diabetes mellitus Journal of Clinical Pharmacology 50 2010 623 635
44. E.K. Hussey, R.L. Dobbins, R.R. Stoltz, N.L. Stockman, R.L. O'Connor-Semmes, and A. Kapur Multiple-dose pharmacokinetics and pharmacodynamics of sergliflozin etabonate, a novel inhibitor of glucose reabsorption, in healthy overweight and obese subjects: a randomized double-blind study Journal of Clinical Pharmacology 50 2010 636 646
45. A.W. Patrick, M.D. Oliver, A.F. Howie, J. Dawes, C.C. Macintyre, and B.M. Frier Urinary excretion of beta-thromboglobulin and N-acetyl-beta-d- glucosaminidase in type 1 diabetes: potential indicators of ealy nephropathy? Diabetes and Metabolism 16 1990 441 447
46. E. Ferrannini, S.J. Ramos, A. Salsali, W. Tang, and J.F. List Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial Diabetes Care 33 2010 2217 2224
47. J.P. Wilding, P. Norwood, C. T'joen, A. Bastien, J.F. List, and F.T. Fiedorek A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment Diabetes Care 32 2009 1656 1662
48. C.J. Bailey, J.L. Gross, A. Pieters, A. Bastien, and J.F. List Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial Lancet 375 2010 2223 2233
49. L. Zhang, Y. Feng, J. List, S. Kasichayanula, and M. Pfister Dapagliflozin treatment in patients with different stages of type 2 diabetes mellitus: effects on glycaemic control and body weight Diabetes, Obesity and Metabolism 12 2010 510 516
50. R.K. Ghosh, S.M. Ghosh, S. Chawla, and S.A. Jasdanwala SGLT2 inhibitors: a new emerging therapeutic class in the treatment of type 2 diabetes melltus Journal of Clinical Pharmacology 52 2012 457 463